Zydus生命科学在古吉拉特邦的API工厂检查后, 面临六次美国林业发展局的观察。 Zydus Lifesciences faces six US FDA observations after an API plant inspection in Gujarat.

印度制药公司Zydus LifeSciences最近视察了设在古吉拉特的API制造单位后,收到了美国食品和药物管理局(USFDA)的六份意见。 Zydus Lifesciences, an Indian pharmaceutical firm, received six observations from the US Food and Drug Administration (USFDA) following a recent inspection of its API manufacturing unit in Gujarat. 这次检查于2025年4月21日至25日进行。 The inspection took place from April 21-25, 2025. 该公司强调,这些观察都与数据的完整性无关,并表示相信能够迅速解决这些问题。 The company stressed that none of the observations were related to data integrity and expressed confidence in resolving them quickly.